5-Fluorouracil Combined with the Pure [6S]-Stereoisomer of Folinic Acid in High Doses for Treatment of Patients with Advanced Colorectal Carcinoma: A Phase I–II Study of two Consecutive Regimens

  • David Machover
  • Xavier Grison
  • Emma Goldschmidt
  • Jacqueline Zittoun
  • Jean-Pierre Lotz
  • Gerard Metzger
  • Jocelyne Richaud
  • Laurent Hannoun
  • Jeanine Marquet
  • Thierry Guillot
  • Mia Bardon
  • Rémy Salmon
  • Alain Sezeur
  • Serge Mauban
  • Rolland Parc
  • Victor Izrael
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 339)

Abstract

Folinic acid ([6R,S]-5-CHO-FH4) given in concentrations greatly exceeding that required for optimal cell growth, increases the cytotoxic action of 5-fluorouracil (5-FU) and fluorodeoxyuridine (FUdR)] in vitro (1,2,3). Potentiation of the antitumor activity of 5-FU by folinic acid has been demonstrated in patients with gastrointestinal carcinomas (4–10); this has resulted in effective palliative treatment for patients with advanced colorectal adenocarcinoma (607).

Keywords

Diarrhea Methotrexate Folate Dermatitis Rhinitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ullman B, Lee M, Martin Dw Jr, et al: Cytotoxicity of 5-fluoro-2′-deoxyuridine: Requirement for reduced folate cofactors and antagonism by methotrexate. Proc Natl Acad Sci USA 75: 980–983, 1978PubMedCrossRefGoogle Scholar
  2. 2.
    Keyomarsi K, Moran R: Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem 263: 14402–14409, 1988PubMedGoogle Scholar
  3. 3.
    Piedbois P, Buyse M, Rustum Y, et al, for the Advanced Colorectal Cancer Meta-Analysis Project: Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10: 896–903, 1992Google Scholar
  4. 4.
    Machover D, Schwarzenberg L, Goldschmidt E, et al: Treatment of advanced colorectal and gastric carcinomas with 5-FU combined with high-dose folinic acid: A pilot study. Cancer Treat Rep 66: 1803–1807, 1982PubMedGoogle Scholar
  5. 5.
    Arbuck S: Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 63: 1036–1044, 1989PubMedCrossRefGoogle Scholar
  6. 6.
    Erlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469–475, 1988PubMedGoogle Scholar
  7. 7.
    Poon Ma, O’Connell Mj, Moertel Cg, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407–1417, 1989PubMedGoogle Scholar
  8. 8.
    Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: 1559–1565, 1987PubMedGoogle Scholar
  9. 9.
    Petrelli N, Douglass Ho, Jr, Herrera L, et al: The modulation of 5-fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 7: 1419–1426, 1989PubMedGoogle Scholar
  10. 10.
    Doroshow Jh, Multhauf P, Leong L, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8: 491–501, 1990PubMedGoogle Scholar
  11. 11.
    Levans RM, Laskin JD, Hakala MT: Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3288–3295, 1981Google Scholar
  12. 12.
    Swain SM, Lippman ME, Egan EF, et al: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890–899, 1989PubMedGoogle Scholar
  13. 12.
    Lockshin A, Danenberg Pv: Biochemical factors affecting the tightness of 5-ftuorodeoxyuridylate binding to human thymidylate synthetase. Biochem Pharmacol 30: 247–257, 1981PubMedCrossRefGoogle Scholar
  14. 14.
    Houghton JA, Williams LG, Cheshire PJ, et al: Influence of dose of [6RS] leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts. Cancer Res 50: 3940–3946, 1990PubMedGoogle Scholar
  15. 15.
    Machover D: Potentiation of the antitumor activity of the fluoropyrimidines by leucovorin: Rationale and clinical data. In: Pinedo HM, Rustum YM, eds. Leucovorin modulation of fluoropyrimidines: A new frontier in cancer chemotherapy. International congress and symposium series number 158. London — New York: Royal Society of Medicine Services, 1989: 1–9Google Scholar
  16. 16.
    Valone Fh, Friedman Ma, Wittlinger Ps, et al: Treatment of patients with advanced colorectal carcinomas with 5-fluorouracil alone, high-dose leucovorin plus 5-fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 7: 1427–1436, 1989PubMedGoogle Scholar
  17. 17.
    White JC, Bailey BD, Goldman ID: Lack of stereospecificity at carbon 6 of methyltetrahydrofoiate transport in Ehrlich ascites tumor cells. Carrier-mediated transport of both stereoisomers. J Biol Chem 253: 242–245, 1978PubMedGoogle Scholar
  18. 18.
    Sirotnak FM, Chello PL, Moccio DM, et al: Stereospecificity at carbon 6 of formyltetrahydrofolate as a competitive inhibitor of transport and cytotoxicity of methotrexate in vitro. Biochem Pharmacol 28: 2993–2997, 1979PubMedCrossRefGoogle Scholar
  19. 19.
    Bertrand R, Jolivet J: Lack of interference by the unnatural isomer of 5-formyltetrahydrofolate with the effects of the natural isomer in leucovorin preparations. J Natl Cancer Inst 81: 1175–1178, 1989PubMedCrossRefGoogle Scholar
  20. 20.
    Sato JK, Moran RG: Interaction of methotrexate and citrovorum factor at folyl polyglutamate synthetase. Proc Am Assoc Cancer Res 3: 312, 1984 (abstr)Google Scholar
  21. 21.
    Romanini A, Lin Jt, Niedzwiecki D, et al: Role of polyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res 51: 789–793, 1991PubMedGoogle Scholar
  22. 22.
    Radvadpar S, Houghton PJ, Houghton JA: Effect of poiyglutamylation of 5, 10-methylenetetrahydrofolate on the binding of 5-fluoro-2′-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol 38: 335–342, 1989CrossRefGoogle Scholar
  23. 23.
    Machover D, Goldschmidt E, Chollet P, et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4: 685–696, 1986PubMedGoogle Scholar
  24. 24.
    Newman EM, Straw JA, Doroshow JH: Pharmacokinetics of diastereoisomers of [6R,S]-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. Cancer Res 49: 5755–5760, 1989.PubMedGoogle Scholar
  25. 25.
    Zhang Zg, Rustum Ym: Effects of diastereoisomers of 5-formyltetrahydrofolate on cellular growth, sensitivity to 5-fluoro-2′-deoxyuridine, and methylenetetrahydrofolate polygliitamate levels in HCT-8 cells. Cancer Res 51: 3476–3481, 1991PubMedGoogle Scholar
  26. 26.
    Mcguire Jj, Russell Ca. Biological and biochemical properties of the natural (6S) and the unnatural (6R) isomers of leucovorin and their racemic (6R,S) mixture. J Cell Pharmacol 2: 317–323, 1991Google Scholar
  27. 27.
    Machover D, Grison X, Goldschmidt E et al. 5-Fluorouracil combined with the pure [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study. J Natl Cancer Inst 84: 321–327, 1992PubMedCrossRefGoogle Scholar
  28. 28.
    Who Handbook for reporting results of cancer treatment. Geneva, World Health Organization, 1979Google Scholar
  29. 29.
    Moran Rg, Scanlon Kl: Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 51: 4618–4623, 1991PubMedGoogle Scholar
  30. 30.
    Wright JE, Dreyfuss A, El-Magharbel I, et al: Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. Cancer Res 49: 2592–2596, 1989PubMedGoogle Scholar
  31. 31.
    Houghton JA, Williams LG,, de Graaf SSN et al: Relationship between dose rate of [6RS]-leucovorin administration, plasma concentrations of reduced folates, and pools of 5, 10-methylene tetrahydrofolates and tetrahydrotblates in human adenocarcinoma xenografts. Cancer Res 50: 3493–3502, 1990PubMedGoogle Scholar
  32. 32.
    Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 7: 425–432, 1989PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • David Machover
    • 1
  • Xavier Grison
    • 1
  • Emma Goldschmidt
    • 2
  • Jacqueline Zittoun
    • 3
  • Jean-Pierre Lotz
    • 1
  • Gerard Metzger
    • 2
  • Jocelyne Richaud
    • 4
  • Laurent Hannoun
    • 5
  • Jeanine Marquet
    • 3
  • Thierry Guillot
    • 6
  • Mia Bardon
    • 6
  • Rémy Salmon
    • 7
  • Alain Sezeur
    • 8
  • Serge Mauban
    • 1
  • Rolland Parc
    • 6
  • Victor Izrael
    • 1
  1. 1.Department of OncologyHospital TenonParisFrance
  2. 2.Service of Hematology and OncologyHospital Paul BrousseVillejuifFrance
  3. 3.Service of Hematology and ImmunologyHospital Henri MondorCréteilFrance
  4. 4.Service of RadiologyHospital TenonParisFrance
  5. 5.Service of SurgeryHospital Saint AntoineParisFrance
  6. 6.Lederle LaboratoriesRungisFrance
  7. 7.Service of SurgeryInstitut CurieParisFrance
  8. 8.Service of SurgeryHospital RothschildParisFrance

Personalised recommendations